Latest Content

An 18-year analysis of a foundation program found trial-related travel, lodging, and caregiving costs varied by income, distance, and trial phase.

Coral Omene, MD, PhD, discusses the clinical impact of breast cancer disparities and how oncology nurses can support diverse trial recruitment.

Jessica Miles, MS, RN, CNS, explains how bench testing showed pumps and filters did not compromise stem cell infusion safety.

The oral CSF-1R inhibitor produced a 54% response rate vs 3% with placebo at week 25 in the phase 3 MANEUVER trial.

An ONS review presented at EONS19 outlines 7 system-level employer strategies to curb oncology nurse burnout and improve retention.

Daisy Molina, EdD, MSN, RNC-LRN, discusses listening, honest reassurance, and lifelong communication skills for nurses facing hard conversations.

In 1,071 women diagnosed at 40 or younger, lower income was tied to delayed presentation and younger age to delayed diagnosis.

A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.

A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.

In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.

Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.

FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma.

Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.